Department of Surgery, Temple University Hospital, Philadelphia, Pa.
J Thorac Cardiovasc Surg. 2013 Dec;146(6):1538-43. doi: 10.1016/j.jtcvs.2013.06.028. Epub 2013 Aug 1.
International Society of Heart and Lung Transplantation guidelines for adult heart transplantation (HT) suggest a donor to recipient body weight ratio (WR) of greater than 0.8. For female to male transplants, a WR of greater than 0.9 is recommended.
The United Network for Organ Sharing database was examined for adult HT from 1999 to 2011. Controls with a WR of 0.9 or greater (normal donor to recipient weight ratio) were compared with patients with a WR of 0.6 to 0.89 (WRL) and a WR of less than 0.59 (WRVL). The primary measured outcome was survival.
Of the 21,928 patients undergoing HT, 14,592 (66.6%) were performed with a normal donor to recipient weight ratio, 7212 (32.9%) were performed with WRL, and 124 (0.6%) were performed with WRVL. In male donor to male recipient, male donor to female recipient, and female donor to female recipient HT, the use of WRL did not influence median survival (P = .3621) and was not associated with increased mortality (P = .7273). In female donor to male recipient HT, WRL was associated with decreased median survival (435 days, P = .0241) and was associated with increased mortality (hazard ratio, 1.201; P = .0383).
HT can be safely performed using WRL donors between sex-matched and male to female transplants. However, in female to male transplants, WRL donors are associated with decreased survival. Although clinical circumstances will guide decision making, consensus criteria may be revisited to liberalize the pool of acceptable donors in an era of unprecedented donor shortage.
国际心肺移植学会成人心脏移植指南建议供体与受体体重比(WR)大于 0.8。对于女性到男性的移植,建议 WR 大于 0.9。
检查了 1999 年至 2011 年期间美国器官共享网络数据库中的成人心脏移植数据。将 WR 为 0.9 或更高(正常供体与受体体重比)的对照组与 WR 为 0.6 至 0.89(WR-L)和 WR 小于 0.59(WR-VL)的患者进行比较。主要测量结果是存活率。
在 21928 例接受心脏移植的患者中,14592 例(66.6%)采用正常供体与受体体重比,7212 例(32.9%)采用 WR-L,124 例(0.6%)采用 WR-VL。在男性供体到男性受体、男性供体到女性受体和女性供体到女性受体心脏移植中,使用 WR-L 并不影响中位生存期(P=0.3621),也与死亡率增加无关(P=0.7273)。在女性供体到男性受体心脏移植中,WR-L 与中位生存期缩短相关(435 天,P=0.0241),且死亡率增加(危险比,1.201;P=0.0383)。
WR-L 供体可安全用于性别匹配和男性到女性的心脏移植。然而,在女性到男性的移植中,WR-L 供体与存活率降低相关。尽管临床情况将指导决策,但在供体严重短缺的时代,共识标准可能需要重新修订,以放宽可接受供体的范围。